文献速递肺外科

可切除非小细胞肺癌袖状肺切除术前新辅助化疗与新辅助放化疗比较

Neoadjuvant Chemotherapy vs Chemoradiation Therapy Followed by Sleeve Resection for Resectable Lung Cancer.
PubMed 文献 · Ann Thorac Surg · 2022-03-26

基于美国国家癌症数据库2006至2017年176例接受袖状肺切除的局部晚期非小细胞肺癌患者,比较新辅助化疗 alone(92例)与新辅助放化疗(84例)的短期和长期结局。新辅助放化疗组90天死亡率更高(11.96% vs 2.38%,P=.015),两组总生存无差异(P=.621)。

要点

  • 新辅助放化疗组90天死亡率11.96%,显著高于新辅助化疗组的2.38%(P=.015)。
  • 两组总生存无显著差异(P=.621)。
  • 新辅助放化疗与90天死亡率增加约5倍相关,且无总生存获益。

核心结论

  • 在需要袖状肺切除的局部晚期可切除非小细胞肺癌患者中,新辅助放化疗与90天死亡率增加约5倍相关,且相比新辅助化疗 alone 无总生存获益。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症数据库识别2006年至2017年间接受新辅助化疗 alone 或新辅助放化疗后行袖状肺切除的局部晚期非小细胞肺癌患者,共176例。
  • 采用倾向性评分调整、逻辑回归、Kaplan-Meier生存分析和Cox比例风险模型分析30天死亡率、90天死亡率和总生存。

主要发现

  • 176例接受袖状肺切除的患者中,92例(52.3%)接受新辅助化疗 alone,84例(47.7%)接受新辅助放化疗。
  • 两组在年龄、性别、种族、Charlson-Deyo合并症指数、保险状态、中位收入和教育程度上均衡(所有P > .05)。
  • 两组在组织学类型、肿瘤位置和分期上均衡(所有P > .05)。
  • 新辅助放化疗组90天死亡率高于新辅助化疗 alone 组(11.96% vs 2.38%,P = .015)。
  • 新辅助化疗 alone 组与新辅助放化疗组的总生存无差异(P = .621)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Traditionally, neoadjuvant chemoradiation therapy is followed by resection in patients with locally advanced non-small cell lung cancer (NSCLC). The risks and benefits of this approach are not well defined in patients requiring a sleeve lung resection. In this context, we compare the short- and long-term outcomes of neoadjuvant chemotherapy alone vs chemoradiation therapy followed by sleeve lung resection. METHODS: We used the National Cancer Database to identify locally advanced NSCLC patients who received chemotherapy-alone or chemoradiation therapy in the neoadjuvant setting, followed by a sleeve lung resection, between 2006 and 2017. Our outcomes of interest were 30-day mortality, 90-day mortality, and overall survival. To minimize confounding by indication, we used propensity score adjustment, logistic regression, Kaplan-Meier survival analysis, and Cox proportional hazards models to identify associations. RESULTS: Of 176 patients undergoing sleeve lung resection, 92 (52.3%) received neoadjuvant chemotherapy-alone, and 84 (47.7%) received neoadjuvant chemoradiation therapy. Patients in both groups were well balanced in age, sex, race, Charlson-Deyo comorbidity index, insurance status, median income, and education (all P > .05). Similarly, the groups were well balanced in histology, tumor location, and stage (all P > .05). Patients receiving neoadjuvant chemoradiation therapy had higher 90-day mortality (11.96% vs 2.38%, P = .015), and there was no difference in overall survival between the neoadjuvant chemotherapy-alone vs chemoradiation therapy cohorts (P = .621). CONCLUSIONS: In this national study of patients with locally advanced resectable NSCLC requiring a sleeve lung resection, neoadjuvant chemoradiation therapy was associated with a 5-fold increase in 90-day mortality without an overall survival benefit over neoadjuvant chemotherapy-alone.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Jaradeh M, Vigneswaran WT, Raad W, et al. Neoadjuvant Chemotherapy vs Chemoradiation Therapy Followed by Sleeve Resection for Resectable Lung Cancer. Ann Thorac Surg. 2022. PMID: 35351422. doi:10.1016/j.athoracsur.2022.03.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。